– CANADA, Dieppe – Triple Hair Group Inc., a company specializing in the development of innovative treatments for androgenic alopecia, announced the appointment of Paul Sowyrda to its Board of Directors.
About Paul Sowyrda
Paul Sowyrda is an accomplished executive and inventor with over 30 years of experience in the pharmaceutical and biotechnology sectors. He co-founded Novellus, Inc. and served as its EVP until its acquisition by Brooklyn ImmunoTherapeutics in 2021. Paul Sowyrda has held key leadership roles, including VP of Drug Development at CIBA, VP of Development and Marketing at Dusa Pharmaceuticals, and VP of Product Development for Chiron Corporation.
A prolific inventor, Paul Sowyrda holds more than 15 patents across various fields, demonstrating his commitment to innovation. He has also contributed to the industry through his service on the Board of Directors for The Society of Concurrent Product Development and as a member of both the American Academy of Dermatology and the International Society of Dermatologic Surgery.
Paul Sowyrda earned his B.S. from Northeastern University, an M.S. from the University of Notre Dame, and an MBA from Babson College, along with completing the MIT Sloan School of Management Senior Executives Program. He resides in Boston and is actively involved in advancing cellular therapy solutions.
About Triple Hair
Triple Hair Group Inc. is a Canadian biotechnology company dedicated to developing innovative, clinically proven treatments for men and women suffering from androgenic alopecia. Triple Hair’s mission is to provide effective prescription hair regrowth treatments for an underserved global market valued at US$8.8 billion in 2023, and expected to reach US$16 billion by 2030. Triple Hair also offers patented over-the-counter natural hair growth products under its RIZN and Plenty Natural brands.
For more information: https://triplehair.ca/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.